Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
|
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [41] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
    Jiang, R.
    Wang, X.
    Wang, L.
    Huang, D.
    Ding, C.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
  • [42] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
    Nakagawa, T.
    Fukuhara, T.
    Imai, K.
    Igusa, R.
    Yokota, H.
    Watanabe, K.
    Suzuki, A.
    Morita, M.
    Inoue, A.
    Miura, M.
    Minamiya, Y.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S953 - S954
  • [43] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
    Hochmair, Maximilian J.
    Holzer, Sophia
    Filipits, Martin
    Mohn-Staudner, Andrea
    Arns, Madeleine
    Errhalt, Peter
    Absenger, Gudrun
    Koller-Herzog, Ursula
    Setinek, Ulrike
    Haslbauer, Ferdinand
    Korger, Mark A.
    Patocka, Kurt
    Kolb, Rainer
    Burghuber, Otto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
    Hochmair, Maximilian
    Holzer, Sophia
    Filipits, Martin
    Mohn-Staudner, Andrea
    Errhalt, Peter
    Absenger, Gudrun
    Bundalo, Tatjana
    Arns, Madeleine
    Setinek, Ulrike
    Mikes, Romana
    Kolb, Rainer
    Schumacher, Michael
    Zoechbauer-Mueller, Sabine
    Patocka, Kurt
    Haslbauer, Ferdinand
    Rudzki, Jakob
    Burghuber, Otto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
  • [45] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [46] Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
    Ohe, Y.
    Kato, T.
    Shimizu, W.
    Sakamoto, K.
    Sugeno, M.
    Tamura, R.
    Tokimoto, T.
    Gemma, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S852 - S852
  • [47] Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study
    Qin, Yi
    Long, Yaling
    Tang, Yuan
    Tian, Yuke
    Li, Juan
    Duan, Ping
    Luo, Jieyan
    Yu, Min
    Li, Yanying
    Zhou, Xiaojuan
    Wang, Ke
    Gong, Youling
    Peng, Feng
    Zhu, Jiang
    Liu, Yongmei
    Zhou, Lin
    Lu, You
    Huang, Meijuan
    CANCER SCIENCE, 2023, 114 (06) : 2552 - 2559
  • [48] EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
    Holzer, Sophia
    Hochmair, Maximilian
    Filipits, Martin
    Mohn-Staudner, Andrea
    Errhalt, Peter
    Absenger, Gudrun
    Bundalo, Tatjana
    Arns, Britt-Madelaine
    Setinek, Ulrike
    Mikes, Romana
    Kolb, Rainer
    Schumacher, Michael
    Zoechbauer-Mueller, Sabine
    Patocka, Kurt
    Haslbauer, Ferdinand
    Rudzki, Jakob
    Burghuber, Otto Chris
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 769 - 770
  • [49] Spectrum of Cancer Types in Kindreds with NSCLC and EGFR T790M Mutations: Results from INHERIT EGFR
    Wiesner, Georgia
    Ashworth, Renee
    Heng, Jennifer C.
    Rainville, Irene
    Mcreynolds, Katharine
    Sable-Hunt, Alicia
    Garber, Judy
    Carbone, David P.
    Oxnard, Geoffrey R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S216 - S216
  • [50] Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M
    Masuhiro, Kentaro
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Takata, So
    Nasu, Shingo
    Takada, Hiromune
    Morita, Satomu
    Tanaka, Ayako
    Morishita, Naoko
    Okamoto, Norio
    Hirashima, Tomonori
    ANTICANCER RESEARCH, 2018, 38 (06) : 3567 - 3571
12345